Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis

NCT ID: NCT02088216


Title
Effect of Long-term, High-dose N-acetylcysteine on Acute Exacerbations of Patients With Non-cystic Fibrosis Bronchiectasis: the BENE Randomized, Controlled Trial
Purpose
Objective: To evaluate whether long-term oral N-acetylcysteine as an expectorant drug can reduce the frequency of acute exacerbations of patients with non-cystic fibrosis bronchiectasis and improve their quality of life. Methods: Patients with non-cystic fibrosis bronchiectasis will be randomly assigned to the observer group (participants receive 600 mg of oral N-acetylcysteine BID for 12 months) or the control group (participants receive oral tablet BID for 12 months). The primary endpoint was the frequency of acute exacerbations. Expected results: Compared with the control group, the frequency of acute exacerbations of the observer Group will decrease significantly. Hypothesis: Long-term oral N-acetylcysteine can reduce the frequency of acute exacerbations of patients with non-cystic fibrosis bronchiectasis and improve their quality of life.
Details
Conditions
Non-Cystic Fibrosis Bronchiectasis
Keywords
N-acetylcysteine;, Bronchiectasis;, Acute exacerbations;, Antioxidant;, Anti-inflammatory
Source
Qilu Hospital
Sponsors
Qilu Hospital
Status
Active, not recruiting
Acronym
BENE
Last Updated
22 Jul 2016
URL
Official Link
Locations
China